# EDGAR Filing Document

**Accession Number:** 0001837607
**File Stem:** 0001104659-23-003086
**Filing Date:** 2023-1
**Character Count:** 15358
**Document Hash:** 979430e4bed276171a3c5dc2df49a966
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-003086.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001104659-23-003086

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230108

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Priveterra Acquisition Corp.
- **CENTRAL INDEX KEY:** 0001837607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 853940478
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40021
- **FILM NUMBER:** 23524069

**BUSINESS ADDRESS:**
- **STREET 1:** 300 SE 2ND STREET
- **STREET 2:** SUITE 600
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301
- **BUSINESS PHONE:** (407) 808-1335

**MAIL ADDRESS:**
- **STREET 1:** 300 SE 2ND STREET
- **STREET 2:** SUITE 600
- **CITY:** FORT LAUDERDALE
- **STATE:** FL
- **ZIP:** 33301

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 8, 2023**

**PRIVETERRA ACQUISITION CORP.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40021** | **85-3940478** |
| (State or other jurisdiction of<br> incorporation) | (Commission <br> File Number) | (IRS Employer <br> Identification No.) |

---

**300 SE 2nd Street, Suite 600 Fort Lauderdale, Florida 33301**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(754) 220-9229**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

⌧ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading <br> Symbol(s)** | **Name of each exchange on which <br> registered** |
| **Units, each consisting of one share of Class A common stock and one-third of one redeemable warrant** | **PMGMU** | **The Nasdaq Stock Market LLC** |
| **Class A common stock, par value $0.0001 per share** | **PMGM** | **The Nasdaq Stock Market LLC** |
| **Redeemable warrants, each warrant exercisable for one share of Class A common stock at an exercise price of $11.50** | **PMGMW** | **The Nasdaq Stock Market LLC** |

---

---

| | |
|:---|:---|
| **Item 1.01** | **Entry into a Material Definitive Agreement.** |

---

In connection with the execution of the Business Combination Agreement, AEON Biopharma, Inc. ("AEON") **a**nd Priveterra Acquisition Corp. ("Priveterra") entered into interim financing letter agreements for an aggregate amount of $20 million (the "Letter Agreements") with certain investors (the "Investors"), the terms of which provide for the sale and issuance to the Investors of an issued security that will be exchanged or converted at the closing of the Business Combination Agreement (the "Closing") into Class A Common Stock of Priveterra at a purchase price of $7.00 per Priveterra share. The Letter Agreements will terminate upon the earliest of (a) such date and time as the Business Combination Agreement is validly terminated, (b) upon mutual written agreement of each of the parties to the Letter Agreements, (c) at any time upon the election of Priveterra and AEON at their sole discretion and (d) nine months from the date of the Letter Agreement**s** if the closing of the Business Combination Agreement has not occurred.

The foregoing description of the Letter Agreements is not complete and is qualified in its entirety by reference to the Letter Agreements, the form of which is attached as Exhibit 10.1 to this Current Report and incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [10.1](tm233165d1_ex10-1.htm) | [Form of Letter Agreement](tm233165d1_ex10-1.htm) |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **Priveterra Acquisition Corp.** | **Priveterra Acquisition Corp.** |
| By: | /s/ Robert Palmisano |
| Name: | Robert Palmisano |
| Title: | Chairman and Chief Executive Officer |

---

Dated: January 11, 2023

## Exhibit 10.1

**Exhibit 10.1**

**AEON BIOPHARMA, INC.**

5 Park Plaza, Suite 1750

Irvine, California 92614

January [●], 2023

[INVESTOR]<br> [ADDRESS]<br> [CITY, STATE, ZIP]

To Whom it May Concern:

Reference is made to that certain Business Combination Agreement, dated December 12, 2022, by and among Priveterra Acquisition Corp., a Delaware corporation ("<u>Priveterra</u>"), Priveterra Merger Sub, Inc., a Delaware corporation, and AEON Biopharma, Inc. ("<u>AEON</u>", such agreement, the "<u>Business Combination Agreement</u>," and, such proposed business combination, the "<u>Business Combination</u>"). This binding letter agreement (this "<u>Letter Agreement</u>") sets forth the principal terms upon which **[●]** ("<u>Investor</u>") agrees to provide a portion of the interim financing (the "<u>Investment</u>") in the amount set forth on the signature page hereto (the "<u>Commitment Amount</u>"), in connection with the Business Combination. Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Business Combination Agreement.

In consideration for the mutual promises made herein and other good and valuable consideration, each of AEON, Priveterra and the Investor, as applicable, agree to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Subject to the terms and conditions hereof, at the Closing (as defined below), the Investor hereby agrees, substantially concurrently with the consummation of the Business Combination, to irrevocably subscribe for and purchase from the Issuer (as defined in <u>Exhibit A</u> hereto), and the Issuer hereby agrees to issue and sell to Subscriber, upon the payment of the Commitment Amount, the Securities (as defined in <u>Exhibit A</u> hereto) having the terms set forth on <u>Exhibit A</u> hereto. Notwithstanding anything herein to the contrary, the consummation of the Investment is contingent upon the substantially concurrent occurrence of the closing of the Business Combination (the "<u>Closing</u>"). The Commitment Amount shall be paid in U.S. Dollars by the Investor to the Issuer (or its designee) on the date that is three Business Days prior to the Closing Date by wire transfer of immediately available funds to an account designated in writing to the Investor by the Issuer and shall be promptly returned to the Investor if, for any reason, the Closing does not occur on the anticipated Closing Date; <u>provided</u> that the return of such funds shall not release the Investor from its obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. In the event the Company Bridge Loan is required under the Business Combination Agreement and the Investor, or any other existing debt or equityholder of AEON (or any affiliate thereof, in each case, an "<u>AEON Insider</u>") agrees to provide all or any portion of the Company Bridge Loan Amount, the principal amount of the Company Bridge Loan (and excluding any interest thereon) provided by such AEON Insider(s) shall (i) be treated as an advanced payment of the Commitment Amount (or the applicable portion thereof, it being understood and agreed that the principal amount of the Company Bridge Loan so funded by such AEON Insider (including, for this purpose, any interest thereon) shall be converted into Securities in the manner set forth in this Letter Agreement); (ii) correspondingly reduce the amount of the Commitment Amount due at Closing; and (iii) be deemed to satisfy the Company's obligations with respect to (x) the Company Bridge Loan and (y) the Company Stockholder Interim Financing Commitment, in each case, for all purposes under the Business Combination Agreement for so long as such Company Bridge Loan has been funded and the Company Stockholder Interim Financing Commitment (as adjusted) remains in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Investor, AEON and Priveterra acknowledge and agree that this Letter Agreement constitutes a binding and enforceable agreement between the parties hereto. Following the execution hereof, the parties will negotiate in good faith, finalize and execute such other definitive agreements in respect of the Investment as may deemed appropriate by the Company prior to the Closing (such agreements, the "<u>Definitive Agreements</u>"), which Definitive Agreements may, to the extent specified therein, supersede this Letter Agreement in whole or in part. The Definitive Agreements will contain customary representations, warranties and covenants of the parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. This Letter Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest to occur of (a) such date and time as the Business Combination Agreement is validly terminated in accordance with its terms, (b) upon the mutual written agreement of each of the parties hereto to terminate this Letter Agreement, (c) at any time upon the election of Priveterra and AEON, in their sole discretion, which such election shall be made by such parties by providing five (5) Business Days' written notice to Investor and (d) nine months from the date hereof if the Closing has not occurred; <u>provided</u> that nothing herein will relieve any party from liability for any willful breach hereof prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities or damages arising from such breach. AEON shall notify Investor of the termination of the Business Combination Agreement reasonably promptly after the termination of such agreement.

5. Investor hereby authorizes Priveterra and AEON to publish and disclose in any announcement or disclosure required by the SEC or Nasdaq (including the Registration Statement/Proxy Statement), the Investor's identity and the nature of the Investor's commitments and obligations under this Letter Agreement; provided that Priveterra and AEON make such disclosure available to Investor for review.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Sections 8.2, 8.3, 8.5, 8.6, 8.7, 8.9, 8.10, 8.11, 8.13, 8.14, 8.15, 8.16, 8.17 and 8.18 of the Business Combination Agreement are incorporated into this Letter Agreement by reference, mutatis mutandis.

[*Signature pages follow*]

If the matters described above are acceptable to you, please so indicate by signing a copy of this letter in the place provided below.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| **AEON BIOPHARMA, INC.** | **AEON BIOPHARMA, INC.** | **AEON BIOPHARMA, INC.** |
| By: |  |  |
|  | Name: | Marc Forth |
|  | Title: | Chief Executive Officer |
| **PRIVETERRA ACQUISITION CORP.** | **PRIVETERRA ACQUISITION CORP.** | **PRIVETERRA ACQUISITION CORP.** |
| By: |  |  |
|  | Name: | Oleg Grodnensky |
|  | Title: | Chief Financial Officer |

---

[Signature Page to Letter Agreement]

**INVESTOR**

[ ⧫ ]

By: <br> Name: <br> Title:

---

| |
|:---|
| **Commitment Amount:** |
| **<u>as may be adjusted in accordance with the terms hereof</u>** |

---

[Signature Page to Letter Agreement]

**EXHIBIT A**

**TERMS OF THE SECURITIES**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**Issuer** | &nbsp;&nbsp;AEON or Priveterra, as mutually agreed between AEON and Priveterra (in such capacity, the "Issuer"); provided that if AEON is the issuer, the issuance of such Securities (as defined below) will not be more dilutive to the Company Stockholders (as defined in the Business Combination Agreement, before giving effect to any issuances of the Securities), than if Priveterra was the issuer of such Securities; provided, further, that, and the if AEON is the issuer, AEON and Priveterra agree to amend the Business Combination Agreement accordingly to give effect to such intent. |
| &nbsp;&nbsp;**Security** | &nbsp;&nbsp;A debt, equity or equity-linked security in the Issuer (the "<u>Securities</u>"), that will be redeemed, exchanged or converted at the Closing in Class A Common Stock of Priveterra ("<u>Priveterra Shares</u>"). |
| &nbsp;&nbsp;**Discount** | &nbsp;&nbsp;The Securities shall convert at and/or be issued at a per share price of $7.00 per Priveterra Share (on as converted basis), reflecting a 30% discount to the $10.00 per share price reflected in the Business Combination Agreement. |
| &nbsp;&nbsp;**Assignment of Commitment** | &nbsp;&nbsp;Prior to the Closing, Investor will be permitted to assign a portion of its Commitment Amount to another investor (an "<u>Assignee Investor</u>"); provided that such Assignee Investor executes a written commitment letter substantially similar to this Letter Agreement, whereupon such Assignee Investor shall be responsible for the assigned portion of the Commitment Amount and Investor's Commitment Amount hereunder shall be correspondingly reduced. |
| &nbsp;&nbsp;**Other Agreements** | &nbsp;&nbsp;Upon the Closing, the Investor agrees, to the extent not already a party, to become a party to the Amended & Restated Registration Rights Agreement in the form attached to the Business Combination Agreement. |

---